Abstract |
There is no effective chronic suppressive therapy Burkholderia cepacia complex infection in cystic fibrosis (CF) patients. This was a pilot, open-label clinical trial of tobramycin inhalation powder (TIP) delivered via Podhaler twice daily for 28days in adults and children with CF and chronic B. cepacia complex infection in Toronto, Canada. A total of 10 subjects (4 pediatric, 6 adult patients) were treated. There was a mean drop of 1.4 log (CFU/ml) in sputum bacterial density (p=0.01) and sputum IL-8 levels decreased significantly after 28days of TIP (p=0.04). The mean relative change in FEV1 (L) from Day 0 to Day 28 of TIP administration was a 4.6% increase but this was not statistically significant. The majority of patients (70%) had no or mild adverse events.
|
Authors | Valerie Waters, Yvonne Yau, Trevor Beaudoin, Jillian Wettlaufer, Sean Kevin Tom, Nancy McDonald, Leena Rizvi, Michelle Klingel, Felix Ratjen, Elizabeth Tullis |
Journal | Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
(J Cyst Fibros)
Vol. 16
Issue 4
Pg. 492-495
(Jul 2017)
ISSN: 1873-5010 [Electronic] Netherlands |
PMID | 28262569
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Anti-Bacterial Agents
- Tobramycin
|
Topics |
- Administration, Inhalation
- Adolescent
- Adult
- Anti-Bacterial Agents
(administration & dosage)
- Burkholderia Infections
(diagnosis, drug therapy)
- Burkholderia cepacia complex
(drug effects, isolation & purification)
- Canada
(epidemiology)
- Child
- Cystic Fibrosis
(drug therapy, microbiology, physiopathology)
- Drug Monitoring
(methods)
- Female
- Forced Expiratory Volume
- Humans
- Male
- Pilot Projects
- Respiratory Tract Infections
(diagnosis, drug therapy, microbiology)
- Sputum
(microbiology)
- Tobramycin
(administration & dosage)
- Treatment Outcome
|